Apatinib Combined With SOX Neoadjuvant Therapy for Locally Advanced Gastric Cancer
We star a multicentre, one-armed, clinical pilot trial intends to investigate the safety and effectiveness of Apatinib Combined With Oxaliplatin, Gimeracil and Oteracil Porassium Capsules Neoadjuvant Ttherapy for Locally Advanced Gastric Cancer(cT2-4/N+M0)
Apatinib Combined|SOX|Neoadjuvant Therapy|Locally Advanced Gastric Cancer
DRUG: ApatinibMesylateTablets
Radical surgical resection rate, Radical surgical resection rate is defined as the rate of R0 resection, 30 days
Pathological response rate, Briefly, pathCR (Pathological complete rate) was defined as an absence of carcinoma cells in the primary site, and pathologic partial response (pathPR) was defined as less than 10% residual carcinoma cells in the specimen., 30 days|overall response rate, according to Response Evaluation Criteria in Solid Tumors RECIST Version 1.1, 30 days|5-year overall survival rate, 60 months|5-year disease free survival rate, 60months|overall postoperative morbidity rates, Refers to the incidence of early postoperative complications. The early postoperative complication are defined as the event observed within 30 days after surgery., 30 days|Duration of postoperative hospital stay, Duration of postoperative hospital stay in days is used to assess the postoperative recovery course., 30 days|30 days mortality rates, Defined as the event observed within 30 days after surgery., 30 days|adverse event, An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An adverse event (AE) can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product., 60 months
We star a multicentre, one-armed, clinical pilot trial intends to investigate the safety and effectiveness of Apatinib Combined With Oxaliplatin, Gimeracil and Oteracil Porassium Capsules Neoadjuvant Ttherapy for Locally Advanced Gastric Cancer(cT2-4/N+M0)